{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:13:11Z","timestamp":1769832791939,"version":"3.49.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bulcan.2021.03.014","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:05:49Z","timestamp":1625735149000},"page":"953-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Virus de l\u2019immunod\u00e9ficience humaine et lymphome"],"prefix":"10.1016","volume":"108","author":[{"given":"Illias","family":"Tazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima Zahra","family":"Lahlimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.03.014_bib0600","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.23487","article-title":"Cancer risk in people infected with human immunodeficiency virus in the United States","volume":"123","author":"Engels","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0605","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1002\/cncr.25530","article-title":"Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era:1984\u00a0to 2007","volume":"116","author":"Seaberg","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0610","series-title":"WHO classification of Tumors of Haematopoietic and Lymphoid Tissues, revised 4th Edition","article-title":"Immunodeficiency-associated lymphoproliferative disorders","year":"2017"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0615","first-page":"442","article-title":"Acquired immunodeficiency syndrome-related lymphoma: clinical aspects","volume":"27","author":"Levine","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0620","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","article-title":"Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States","volume":"117","author":"Simard","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0625","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/QAI.0b013e31817efb54","article-title":"Changes in causes of death among adults infected by HIV between 2000\u00a0and 2005: the \u201cMortalit\u00e9 2000\u00a0and 2005\u201d surveys (ANRS EN19\u00a0and Mortavic)","volume":"48","author":"Lewden","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0630","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2138259","article-title":"Risk of cancer among commercially insured HIV-infected adults on antiretroviral therapy","volume":"2016","author":"Lee","year":"2016","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0635","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/S2352-3018(18)30179-6","article-title":"Incidence of first and second primary cancers diagnosed among people with HIV, 1985\u20132013: a population-based, registery linkage study","volume":"5","author":"Hessol","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0640","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546\u00a0patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0645","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ajh.23236","article-title":"Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and hodgkin's lymphoma and its correlation with antiretroviral therapy","volume":"87","author":"Bibas","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0650","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996\u00a0to 2012: a population-based, registry-linkage study","volume":"4","author":"Hernandez-Ramirez","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0655","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.V98.8.2339","article-title":"Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy","volume":"98","author":"Besson","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0660","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","article-title":"Epidemiology of haematological malignancies in people living with HIV","volume":"7","author":"Kimani","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0665","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0670","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood-2008-09-180315","article-title":"HIV-associated lymphomas and gamma-herpesviruses","volume":"113","author":"Carbone","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0675","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2005-01-0432","article-title":"Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma","volume":"106","author":"Piriou","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0680","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/QAD.0000000000002461","article-title":"virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV","volume":"34","author":"Besson","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0685","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2009.25.1322","article-title":"Circulating serum free light chains as predictive markers of AIDS-related lymphoma","volume":"28","author":"Landgren","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0690","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hiv.12546","article-title":"The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people","volume":"19","author":"Sherpherd","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0695","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1055-9965.EPI-11-0037","article-title":"B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma","volume":"20","author":"Breen","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0700","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/QAD.0b013e328332d5b1","article-title":"Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study","volume":"24","author":"Wong","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0705","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3851\/IMP1462","article-title":"Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study","volume":"14","author":"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Groupe","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0710","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0b013e3282ed6338","article-title":"Risk of cancers during interrupted antiretroviral therapy in the SMART study","volume":"21","author":"Silverberg","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0715","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(09)70282-7","article-title":"Effect of immunodeficiency, HIV viral\u00a0load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study","volume":"10","author":"Guiguet","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0720","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016\u00a0revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0725","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2013.1.382","article-title":"Update on the treatment of HIV-associated hematologic malignancies","volume":"2013","author":"Little","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0730","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/157016210790442704","article-title":"Hodgkin lymphoma in HIV positive patients","volume":"8","author":"Mounier","year":"2010","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0735","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0740","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0745","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the influence of lymphoma-and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0750","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2004-11-4278","article-title":"AIDS-related lymphoproliferative disease","volume":"107","author":"Navarro","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0755","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00002030-200307040-00013","article-title":"Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma","volume":"17","author":"Hoffmann","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0760","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7326\/0003-4819-143-4-200508160-00007","article-title":"A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy","volume":"143","author":"Bower","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0765","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cncr.21759","volume":"106","author":"Weiss","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0770","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","article-title":"Primary effusion lymphoma","volume":"12","author":"Chen","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0775","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","article-title":"Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study","volume":"27","author":"Schommers","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0780","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","article-title":"A new prognostic score for AIDS-related lymphomas in the rituximab-era","volume":"99","author":"Barta","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0785","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/cncr.29066","article-title":"Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bl\u00e9omycine, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0790","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1468-1293.2008.00608.x","article-title":"British HIV Association guidelines for HIV-associated malignancies 2008","volume":"9","author":"Bower","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0795","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0800","doi-asserted-by":"crossref","first-page":"O672","DOI":"10.1111\/1469-0691.12589","article-title":"Efficacy and safety of antiretrovirals in HIV-infected patients with cancer","volume":"20","author":"Torres","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0805","unstructured":"European AIDS Clinical Society guidelines Version 7\u00a0October 2013 (2013). Part V: Opportunistic infections. http:\/\/www.eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf."},{"key":"10.1016\/j.bulcan.2021.03.014_bib0810","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0815","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3\u00a0trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0820","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","article-title":"Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma","volume":"118","author":"Barta","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0825","first-page":"3755","article-title":"Frequent mutation of the 5\u2019 non coding region of the BCL-6\u00a0gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas","volume":"89","author":"Gaidano","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0830","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/QAD.0b013e328010ac5b","article-title":"Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status","volume":"20","author":"Vaghefi","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0835","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0840","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated large B-cell lymphoma: results of a phase II trial","volume":"140","author":"Ribera","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0845","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3\u00a0phase 2\u00a0trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0850","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0855","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","article-title":"Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era","volume":"31","author":"Besson","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0860","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0865","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.13221","article-title":"Survival of AIDS-relatd diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort","volume":"168","author":"Schommers","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0870","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","article-title":"Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study","volume":"28","author":"Gibson","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0875","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5858\/arpa.2012-0095-RA","article-title":"Lymphoid proliferations associated with human immunodeficiency virus infection","volume":"137","author":"Chadburn","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0880","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<766::AID-CNCR21>3.0.CO;2-V","article-title":"Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75\u00a0patients","volume":"82","author":"Spina","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0885","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2\u00a0study (Burkimab)","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0890","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0895","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","article-title":"Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy","volume":"29","author":"Alwan","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0900","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3109\/10428194.2013.878933","article-title":"Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma\/leukemia: parallel study of 81\u00a0patients","volume":"55","author":"Xicoy","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0905","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0910","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0915","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/modpathol.3800355","article-title":"Plasmablastic plasma cell myelomas have nearly identical immunophenotypic profils","volume":"18","author":"Vega","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0920","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lesson learned from 112\u00a0published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0925","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmblastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0930","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","article-title":"Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study","volume":"27","author":"Schommers","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0935","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8583","article-title":"Treatment of HIV-associated plasmblastic lymphoma: a single-center experience with 25\u00a0patients","volume":"32","author":"Ibrahim","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0940","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3109\/10428194.2015.1113281","article-title":"Plasmablastic lymphoma is treatable in the HAART era. A 10\u00a0year retrospective by the AIDS Malignancy Consortium","volume":"57","author":"Noy","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0945","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428194.2014.911867","article-title":"Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience","volume":"56","author":"Cattaneo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0950","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","article-title":"Hematopoietic cell transplantation for plasmablastic lymphoma: a review","volume":"20","author":"AL-Malki","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0955","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0960","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0965","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/asheducation-2013.1.103","article-title":"Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma","volume":"2013","author":"Kaplan","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0970","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.24251","article-title":"Classic and extracavitary primary effusion lymphoma in 51\u00a0HIV-infected patients from a single institution","volume":"91","author":"Guillet","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0975","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","article-title":"prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS","volume":"23","author":"Boulanger","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0980","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.3109\/10428194.2012.694075","article-title":"Prognosis in primary effusion lymphoma is associated with the number of body cavities involved","volume":"53","author":"Castillo","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0985","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single institution study","volume":"21","author":"Simonelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0990","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0995","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clml.2011.12.003","article-title":"Complete response to EPOCH in a patient with and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature","volume":"12","author":"El-Ayass","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1000","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ajh.10341","article-title":"Combined chemotherapy including high-dose methotrexate in KSHV\/HHV8-associated primary effusion lymphoma","volume":"73","author":"Boulanger","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/108729104322802498","article-title":"Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review","volume":"18","author":"Waddington","year":"2004","journal-title":"AIDS Patient CARE STDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1010","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.clml.2016.02.018","article-title":"Management and outcomes of HIV-associated primary effusion lymphoma: a single center experience","volume":"16Suppl","author":"Gupta","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuke"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1806295","article-title":"Daratumumab in primary effusion lymphoma","volume":"379","author":"Shah","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/QAD.0000000000000030","article-title":"factors associated with survival among patients with AIDS-related primary central nervous system lymphoma","volume":"28","author":"Uldrick","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0046-8177(97)90137-4","article-title":"AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51\u00a0cases. The French Study Group for HIV-associated tumors","volume":"28","author":"Camilleri-Broet","year":"1997","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1030","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0140-6736(91)91837-K","article-title":"Epstein-Barr virus in AIDS-related primary central nervous system lymphoma","volume":"338","author":"Macmahon","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1035","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabaine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2\u00a0trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1212\/WNL.0000000000004265","article-title":"Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy","volume":"89","author":"Moulignier","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/neuonc\/now155","article-title":"Long-term survival in AIDS-related primary central nervous system lymphoma","volume":"19","author":"Gupta","year":"2017","journal-title":"Neuro Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.bulcan.2021.03.014_bib1050","first-page":"1","article-title":"British HIV association guidelines for HIV-associated malignancies 2014","volume":"15","author":"Bower","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1055","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/bmt.2015.18","article-title":"Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT","volume":"50","author":"O\u2019Neil","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1060","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","article-title":"How I treat HIV-associated multicentric Castelman disease","volume":"116","author":"Bower","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1065","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Catleman disease: 273\u00a0patients studied over 20\u00a0years","volume":"180","author":"Oksenhendler","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1070","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.V96.6.2069.h8002069_2069_2073","article-title":"High levels of human herpesvirus 8\u00a0viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric cattleman disease in HIV-infected patients","volume":"96","author":"Oksenhendler","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1075","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdn697","article-title":"The role of immune suppression and HHV-8\u00a0in the increasing incidence of HIV-associated multicentric Castleman's disease","volume":"20","author":"Powles","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1080","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeiciency virus associated multicentric Castleman's disease: ANRS 117\u00a0CastlemaB Trial","volume":"25","author":"G\u00e9rard","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/107327481402100403","article-title":"Diagnosis and management of Castleman disease","volume":"21","author":"Soumerai","year":"2014","journal-title":"Cancer Control"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1090","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2011-02-333633","article-title":"Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease","volume":"118","author":"Hoffmann","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1095","first-page":"e2019004","article-title":"HIV and lymphoma: from epidemiology to clinical management","volume":"11","author":"Re Alessandro","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-7-10","article-title":"Short-term efficacy of the IL6\u00a0receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases","volume":"7","author":"Nagao","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1105","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO.1995.13.7.1758","article-title":"Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114\u00a0patients from the Italian Cooperative Group on AIDS and Tumors","volume":"13","author":"Tirelli","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1110","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/cid\/civ627","article-title":"High risk features contrast with favorable outcomes in HIV-associated Hodgkin Lymphoma in the modern cART era, ANRS CO16\u00a0LYMPHOVIR Cohort","volume":"61","author":"Besson","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1115","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bl\u00e9omycine, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10428194.2016.1201573","article-title":"Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG So816\u00a0phase 2\u00a0trial","volume":"58","author":"Danilov","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1125","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","article-title":"Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study","volume":"30","author":"Hentrich","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1130","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803\/AMC071\u00a0trial","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1135","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3109\/10428194.2012.697560","article-title":"Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma","volume":"53","author":"Ezzat","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1140","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2008.18.2683","article-title":"Autologous stem-cell transplantation in patients with HIV-related lymphoma","volume":"27","author":"Balslobre","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1145","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable survival between HIV+ and HIV non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation","volume":"113","author":"Diez-Martin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbmt.2015.08.006","article-title":"Safety and efficacy of combination antiretroviral therapy in human immunodeficiency virus-infected adults undergoing autologous or allogeneic hematopoietic cell transplantation for hematologic malignancies","volume":"22","author":"Johnston","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1155","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab v\u00e9dotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1160","article-title":"Brentuximab v\u00e9dotin in patients with relapsed HIV-related lymphoma","volume":"12","author":"Ghandi","year":"2014","journal-title":"J Nat Compr Canc Netw"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1165","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2\u00a0trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1170","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-017-0252-3","article-title":"Nivolumab as salvage treatment in a patient with HIV-related relapsed\/refractory Hodgkin lymphoma and liver failure with encephalopathy","volume":"5","author":"Sandoval-Sus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1180","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2013.089052","article-title":"Stem cell mobilization in HIV seropositive patients with lymphoma","volume":"98","author":"Re","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2021.03.014_bib1185","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood.V99.2.698","article-title":"Nonmyeloblative condtitionning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome","volume":"99","author":"Kang","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.03.014_bib0595","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbmt.2009.03.023","article-title":"Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research","volume":"15","author":"Gupta","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:34:57Z","timestamp":1757792097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":119,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0007455121001806"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.03.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus de l\u2019immunod\u00e9ficience humaine et lymphome","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}